Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Join SI Premium – FREE
Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.23), $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $601 thousand versus the consensus estimate of $3.3 million.
For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Meta's capital-raising plans expose a major weakness in the AI boom
- Cheesecake Factory (CAKE) PT Raised to $80 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
